186 related articles for article (PubMed ID: 26876207)
1. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.
Zhou J; Luo J; Wu K; Yun EJ; Kapur P; Pong RC; Du Y; Wang B; Authement C; Hernandez E; Yang J; Xiao G; Cha TL; Wu HC; Wu D; Margulis V; Lotan Y; Brugarolas J; He D; Hsieh JT
Oncogene; 2016 Sep; 35(35):4663-74. PubMed ID: 26876207
[TBL] [Abstract][Full Text] [Related]
2. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.
Santoni M; Pantano F; Amantini C; Nabissi M; Conti A; Burattini L; Zoccoli A; Berardi R; Santoni G; Tonini G; Santini D; Cascinu S
Biochim Biophys Acta; 2014 Apr; 1845(2):221-31. PubMed ID: 24480319
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation.
Yun EJ; Lin CJ; Dang A; Hernandez E; Guo J; Chen WM; Allison J; Kim N; Kapur P; Brugarolas J; Wu K; He D; Lai CH; Lin H; Saha D; Baek ST; Chen BPC; Hsieh JT
Clin Cancer Res; 2019 Jul; 25(14):4542-4551. PubMed ID: 31000589
[TBL] [Abstract][Full Text] [Related]
4. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
6. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
7. DAB2IP stabilizes p27
Zhou J; Deng Z; Pei X; Lai J; Qu W
Funct Integr Genomics; 2023 Oct; 23(4):326. PubMed ID: 37880458
[TBL] [Abstract][Full Text] [Related]
8. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
9. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
11. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Holland WS; Tepper CG; Pietri JE; Chinn DC; Gandara DR; Mack PC; Lara PN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):185-94. PubMed ID: 21644050
[TBL] [Abstract][Full Text] [Related]
12. Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Cho D
Cancer J; 2013; 19(4):311-5. PubMed ID: 23867512
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals.
Yeh CR; Ou ZY; Xiao GQ; Guancial E; Yeh S
Oncotarget; 2015 Dec; 6(42):44346-59. PubMed ID: 26587829
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of DAB2IP in chemoresistance of prostate cancer cells.
Wu K; Xie D; Zou Y; Zhang T; Pong RC; Xiao G; Fazli L; Gleave M; He D; Boothman DA; Hsieh JT
Clin Cancer Res; 2013 Sep; 19(17):4740-9. PubMed ID: 23838317
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
16. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
17. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
18. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Zhang P; Xing Z; Li X; Song Y; Zhao J; Xiao Y; Xing Y
Int J Oncol; 2016 Apr; 48(4):1417-25. PubMed ID: 26820170
[TBL] [Abstract][Full Text] [Related]
20. Adaptive responses to
Fan C; Zhao C; Zhang F; Kesarwani M; Tu Z; Cai X; Davis AK; Xu L; Hochstetler CL; Chen X; Guo F; Huang G; Azam M; Tian W; Lu QR; Zheng Y
Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]